Table 1.

Clinicopathologic characteristics of the University of North Carolina at Chapel Hill melanoma craniotomy cohort (N=62).

Sex
	Male			41
	Female			21
Age at Craniotomy (median), range (years)				55 (30,85)
Race
	Caucasian			59
	Hispanic/Latino			2
	African American			1
Melanoma Subtype
	Cutaneous			45
	Head and Neck			11
	Trunk			18
	Extremity			19
	Multiple primaries			2
	Unknown			5
	Unknown			16
	Mucosal			1
Molecular Characteristics
	Non-tested			23
	Tested			39
	Immunohistochemistry			5
		BRAFV600E-mutant		3
	Pyrosequencing			15
		BRAFV600 mutation (E/K, out of 15 tested)		5 (4/1)
		NRASQ61 mutation (out of 5 tested)		2
		CKIT mutation (out of 5 tested)		1
	Illumina 26-gene panel			12
		BRAFV600 mutation (E/K)		6 (5/1)
		NRASQ61 mutation		3
		PTEN mutation		3
		TP53		1
	FoundationOne			6
		BRAFV600		0
		Non-BRAFV600		2
		NRASQ61 mutation		2
		TERT promoter mutations		4
		CDKN2A mutation/deletion		5
		NF1 splice site/stop codon mutations		4
		Other (PTEN, EZH2, SETD2, RAC1)		4
	UNCseq			1
		BRAFV600		0
		NF1 splice site/stop codon mutations		1
Craniotomy Tumor Specimen Volume (cm3, median, range)			3.97 (0.06, 124.2)
Peritumoral Vasogenic Edema of the Resected Lesion (brain scan)
	Absent			5
	Present, low			32
	Present, high			23
	Not reported			2
Brain Radiation Prior to Craniotomy
	No			55
	Yes			7
Systemic Treatments Prior to Craniotomy
	No			36
	Yes			26
	Immunotherapies			17
		Adjuvant		14
		High-dose interferon		11
		Immune checkpoint inhibitors		3
		For stage IV		5
	Chemotherapies			6
	Targeted Treatments			3
Systemic Treatment After Craniotomy
	No			27
	Yes			35
	Immunotherapies			24
		PD1 inhibitors only		7
		CTLA4 inhibitors only		6
		PD1 and CTLA4 inhibitors		8
		Other (high-dose bolus IL-2, GM-CSF)		3
	Chemotherapies			12
	Targeted Treatments			12
	Unknown			1